Epigallocatechin gallate inhibits the HIV reverse transcription step

Shenwei Li, Toshio Hattori, Eiichi N. Kodama

Research output: Contribution to journalArticlepeer-review

75 Citations (Scopus)


Background: Epigallocatechin gallate (EGCG), the most abundant catechin in green tea, has been reported to inhibit HIV-1 replication prior to its integration into host DNA via various proposed mechanisms; however, the specific main target(s) of EGCG remain unclear. In this study, we investigated a number of these proposed detailed mechanism(s) using a cell-based model. Methods: Multinuclear activation of galactosidase indicator assays were used for all experiments, including examination of the time of addition and the synergisms with a nucleoside reverse transcriptase inhibitor, 3′-azido-3′-deoxythymidine (AZT). Results: The experiments revealed that EGCG suppressed both HIV-1 IIIB and HIV-2 EHO infection in HeLa-CD4-LTR-β- gal cells, with relatively low 50% effective concentrations of 1.6 and 2.0 μM, respectively. The inhibitory profile of EGCG generated using a time-of-addition assay was identical to that of a non-nucleoside reverse transcriptase inhibitor (NNRTI), MKC-442. Furthermore, synergistic inhibition was observed in EGCG with AZT. Conclusions: Based on our findings, EGCG appears to act mainly as an allosteric reverse transcriptase inhibitor with mechanisms different from those of currently approved NNRTIs that directly interact with the NNRTI binding pocket. Thus, EGCG is a good candidate for use as an additional or supportive anti-HIV agent derived from natural plants.

Original languageEnglish
Pages (from-to)239-243
Number of pages5
JournalAntiviral Chemistry and Chemotherapy
Issue number6
Publication statusPublished - 2011


Dive into the research topics of 'Epigallocatechin gallate inhibits the HIV reverse transcription step'. Together they form a unique fingerprint.

Cite this